# XMax Inc.: financial statements, quarterly

XMAX · Nasdaq · CIK 1473334 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xmax.md) · [Financials](/companies/xmax/financials.md) · [Filings](/companies/xmax/filings.md) · [Insiders](/companies/xmax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xmax/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.5](/filings/0001493152-24-045787.md) | [2.3 d](/filings/0001641172-25-001773.md) | [2.4](/filings/0001641172-25-010938.md) | [2.7](/filings/0001641172-25-024041.md) | [2.6](/filings/0001493152-25-023548.md) | [2.0 d](/filings/0001493152-26-016828.md) | [2.6](/filings/0001493152-26-023861.md) | [2.6](/filings/0001493152-26-038444.md) | [9.8](/filings/0001493152-25-023548.md) | [1.8 d](/filings/0001493152-26-016828.md) | [1.8](/filings/0001493152-26-023861.md) | [2.7](/filings/0001493152-26-038444.md) |
| Cost of revenue | $m | [1.4](/filings/0001493152-24-045787.md) | [1.3 d](/filings/0001641172-25-001773.md) | [1.4](/filings/0001641172-25-010938.md) | [1.5](/filings/0001641172-25-024041.md) | [1.4](/filings/0001493152-25-023548.md) | [1.1 d](/filings/0001493152-26-016828.md) | [1.4](/filings/0001493152-26-023861.md) | [1.3](/filings/0001493152-26-038444.md) | [8.8](/filings/0001493152-25-023548.md) | [1.1 d](/filings/0001493152-26-016828.md) | [0.9](/filings/0001493152-26-023861.md) | [1.6](/filings/0001493152-26-038444.md) |
| Gross profit | $m | [1.1](/filings/0001493152-24-045787.md) | [1.0 d](/filings/0001641172-25-001773.md) | [1.0](/filings/0001641172-25-010938.md) | [1.2](/filings/0001641172-25-024041.md) | [1.2](/filings/0001493152-25-023548.md) | [0.9 d](/filings/0001493152-26-016828.md) | [1.2](/filings/0001493152-26-023861.md) | [1.3](/filings/0001493152-26-038444.md) | [1.0](/filings/0001493152-25-023548.md) | [0.7 d](/filings/0001493152-26-016828.md) | [0.9](/filings/0001493152-26-023861.md) | [1.1](/filings/0001493152-26-038444.md) |
| Research and development | $m | not reported | not reported | [0.8](/filings/0001493152-24-019874.md) | not reported | not reported | not reported | [0.0](/filings/0001493152-26-023861.md) | [0.0](/filings/0001493152-26-038444.md) | not reported | not reported | not reported | not reported |
| Operating income | $m | [(1.1)](/filings/0001493152-24-045787.md) | [(3.8) d](/filings/0001641172-25-001773.md) | [(1.5)](/filings/0001641172-25-010938.md) | [(0.5)](/filings/0001641172-25-024041.md) | [(2.4)](/filings/0001493152-25-023548.md) | [(1.0) d](/filings/0001493152-26-016828.md) | [(0.2)](/filings/0001493152-26-023861.md) | [(0.2)](/filings/0001493152-26-038444.md) | [(0.5)](/filings/0001493152-25-023548.md) | [(1.0) d](/filings/0001493152-26-016828.md) | [(0.5)](/filings/0001493152-26-023861.md) | [(1.2)](/filings/0001493152-26-038444.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-26-038444.md) | not reported | not reported | [0.0](/filings/0001493152-26-023861.md) | [0.0](/filings/0001493152-26-038444.md) |
| Income tax | $m | [0.1](/filings/0001493152-24-045787.md) | [0.6 d](/filings/0001641172-25-001773.md) | not reported | [0.0](/filings/0001641172-25-024041.md) | [0.0](/filings/0001493152-25-023548.md) | [(0.0) d](/filings/0001493152-26-016828.md) | [(0.1)](/filings/0001493152-26-023861.md) | [(0.0)](/filings/0001493152-26-038444.md) | [(0.0)](/filings/0001493152-25-023548.md) | [(0.5) d](/filings/0001493152-26-016828.md) | not reported | [7.8](/filings/0001493152-26-038444.md) |
| Net income | $m | [(1.3)](/filings/0001493152-24-045787.md) | [(4.7) d](/filings/0001641172-25-001773.md) | [(1.5)](/filings/0001641172-25-010938.md) | [(0.6)](/filings/0001641172-25-024041.md) | [(2.5)](/filings/0001493152-25-023548.md) | [(1.1) d](/filings/0001493152-26-016828.md) | [(0.3)](/filings/0001493152-26-023861.md) | [(0.3)](/filings/0001493152-26-038444.md) | [(1.1)](/filings/0001493152-25-023548.md) | [(1.7) d](/filings/0001493152-26-016828.md) | [0.2](/filings/0001493152-26-023861.md) | [32.4](/filings/0001493152-26-038444.md) |
| Diluted EPS | $ per share | [(0.83)](/filings/0001493152-24-045787.md) | not reported | [(0.65)](/filings/0001641172-25-010938.md) | [(0.22)](/filings/0001641172-25-024041.md) | [(0.72)](/filings/0001493152-25-023548.md) | not reported | [(0.03)](/filings/0001493152-26-023861.md) | [(0.02)](/filings/0001493152-26-038444.md) | [(0.06)](/filings/0001493152-25-023548.md) | not reported | [0.00](/filings/0001493152-26-023861.md) | [0.53](/filings/0001493152-26-038444.md) |
| Basic EPS | $ per share | [(0.83)](/filings/0001493152-24-045787.md) | not reported | [(0.65)](/filings/0001641172-25-010938.md) | [(0.22)](/filings/0001641172-25-024041.md) | [(0.72)](/filings/0001493152-25-023548.md) | not reported | [(0.03)](/filings/0001493152-26-023861.md) | [(0.02)](/filings/0001493152-26-038444.md) | [(0.06)](/filings/0001493152-25-023548.md) | not reported | [0.00](/filings/0001493152-26-023861.md) | [0.53](/filings/0001493152-26-038444.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.7](/filings/0001493152-23-041292.md) | [0.4](/filings/0001641172-25-001773.md) | [0.3](/filings/0001493152-24-019874.md) | [0.4](/filings/0001493152-24-032235.md) | [0.2](/filings/0001493152-24-045787.md) | [0.2](/filings/0001493152-26-016828.md) | [0.1](/filings/0001641172-25-010938.md) | [0.5](/filings/0001641172-25-024041.md) | [1.7](/filings/0001493152-25-023548.md) | [6.7](/filings/0001493152-26-038444.md) | [9.9](/filings/0001493152-26-023861.md) | [34.6](/filings/0001493152-26-038444.md) |
| Current assets | $m | [3.6](/filings/0001493152-23-041292.md) | [3.7](/filings/0001641172-25-001773.md) | [3.9](/filings/0001493152-24-019874.md) | [3.7](/filings/0001493152-24-032235.md) | [3.1](/filings/0001493152-24-045787.md) | [7.9](/filings/0001493152-26-016828.md) | [10.4](/filings/0001641172-25-010938.md) | [10.2](/filings/0001641172-25-024041.md) | [12.3](/filings/0001493152-25-023548.md) | [11.8](/filings/0001493152-26-038444.md) | [19.7](/filings/0001493152-26-023861.md) | [46.9](/filings/0001493152-26-038444.md) |
| Total assets | $m | [8.5](/filings/0001493152-23-041292.md) | [6.2](/filings/0001641172-25-001773.md) | [6.2](/filings/0001493152-24-019874.md) | [5.8](/filings/0001493152-24-032235.md) | [5.1](/filings/0001493152-24-045787.md) | [9.9](/filings/0001493152-26-016828.md) | [11.9](/filings/0001641172-25-010938.md) | [35.5](/filings/0001493152-26-038444.md) | [18.3](/filings/0001493152-25-023548.md) | [35.5](/filings/0001493152-26-038444.md) | [47.1](/filings/0001493152-26-023861.md) | [121](/filings/0001493152-26-038444.md) |
| Current liabilities | $m | [2.4](/filings/0001493152-23-041292.md) | [3.7](/filings/0001641172-25-001773.md) | [4.3](/filings/0001493152-24-019874.md) | [4.0](/filings/0001493152-24-032235.md) | [4.4](/filings/0001493152-24-045787.md) | [5.8](/filings/0001493152-26-016828.md) | [4.4](/filings/0001641172-25-010938.md) | [4.5](/filings/0001641172-25-024041.md) | [4.4](/filings/0001493152-25-023548.md) | [2.4](/filings/0001493152-26-038444.md) | [1.5](/filings/0001493152-26-023861.md) | [1.6](/filings/0001493152-26-038444.md) |
| Total liabilities | $m | [4.6](/filings/0001493152-23-041292.md) | [5.7](/filings/0001641172-25-001773.md) | [6.2](/filings/0001493152-24-019874.md) | [5.8](/filings/0001493152-24-032235.md) | [6.0](/filings/0001493152-24-045787.md) | [6.8](/filings/0001493152-26-016828.md) | [5.2](/filings/0001641172-25-010938.md) | [5.1](/filings/0001641172-25-024041.md) | [4.7](/filings/0001493152-25-023548.md) | [7.6](/filings/0001493152-26-038444.md) | [6.8](/filings/0001493152-26-023861.md) | [14.8](/filings/0001493152-26-038444.md) |
| Shareholders' equity | $m | [3.9](/filings/0001493152-24-045787.md) | [0.5](/filings/0001493152-26-016828.md) | [(0.0)](/filings/0001641172-25-024041.md) | [0.0](/filings/0001493152-25-023548.md) | [(0.9)](/filings/0001493152-25-023548.md) | [3.1](/filings/0001493152-26-038444.md) | [6.8](/filings/0001493152-26-038444.md) | [6.5](/filings/0001493152-26-038444.md) | [13.6](/filings/0001493152-25-023548.md) | [28.0](/filings/0001493152-26-038444.md) | [40.4](/filings/0001493152-26-038444.md) | [106](/filings/0001493152-26-038444.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [90.5 d](/filings/0001493152-24-045787.md) | [(3,100) d](/filings/0001641172-25-001773.md) | [(222)](/filings/0001641172-25-010938.md) | [(469) d](/filings/0001641172-25-024041.md) | [(438) d](/filings/0001493152-25-023548.md) | [(263) d](/filings/0001493152-26-016828.md) | [(323)](/filings/0001493152-26-023861.md) | [92.5 d](/filings/0001493152-26-038444.md) | [(1,907) d](/filings/0001493152-25-023548.md) | [1,691 d](/filings/0001493152-26-016828.md) | [(642)](/filings/0001493152-26-023861.md) | [(3,648) d](/filings/0001493152-26-038444.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.4](/filings/0001493152-23-041292.md) | [1.4](/filings/0001493152-24-019874.md) | [1.5](/filings/0001493152-24-032235.md) | [1.5](/filings/0001493152-24-045787.md) | [2.2](/filings/0001641172-25-010938.md) | [2.5](/filings/0001641172-25-024041.md) | [3.4](/filings/0001493152-25-023548.md) | [9.8](/filings/0001493152-26-023861.md) | [13.7](/filings/0001493152-26-038444.md) | [18.1](/filings/0001493152-25-023548.md) | [44.8](/filings/0001493152-26-023861.md) | [61.0](/filings/0001493152-26-038444.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,523,426 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038444.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.